Managing CTD-ILD progression with antifibrotics: Clinical insights and guideline updates
10 Mar 2026
byProf. Rohit Aggarwal, Division of Rheumatology, University of Pittsburgh, US
Up to 40 percent of patients with connective tissue disease–associated interstitial lung disease (CTD-ILD) develop progressive pulmonary fibrosis, which requires more intensive management beyond immunosuppressants to control the decline in lung function. At the International Conference of Chinese Rheumatologists 2025, Professor Rohit Aggarwal from the Division of Rheumatology, University of Pittsburgh, US, discussed the therapeutic role of nintedanib as an antifibrotic in CTD-ILD management and shared recent updates from international guidelines.
